Baseline characteristics of the patients
| . | Arm A (n = 97) . | Arm B (n = 98) . |
|---|---|---|
| Sex, M/F, no. of patients | 49/48 | 50/48 |
| Age, y (range) | 53 (35–59) | 54 (34–59) |
| DS stage II/III, no. of patients | 15/82 | 14/84 |
| M component, no. of patients | ||
| IgG | 59 | 57 |
| IgA | 16 | 17 |
| Bence Jones | 22 | 24 |
| Hemoglobin, g/L (range) | 93 (53–121) | 94 (64–120) |
| Serum calcium, mmol/L (range) | 2.4 (2–4) | 2.5 (2.1–4) |
| Serum albumin, g/L (range) | 35 (20–42) | 34 (18–43) |
| Serum β-2 microglobulin, nmol/L (range) | 255 (85–1700) | 246.5 (93.5–1190) |
| Serum creatinine, μmol/L (range) | 100 (46–220) | 95 (43–226) |
| Bone marrow plasmocytosis, % of cells (range) | 35 (20–90) | 39 (25–80) |
| Chromosome 13, no. of patients (conventional cytogenetics) | ||
| No deletion | 56 | 58 |
| Deletion | 13 | 16 |
| Unknown | 28 | 24 |
| International Staging System, no. of patients | ||
| I | 27 | 29 |
| II | 31 | 30 |
| III | 39 | 39 |
| . | Arm A (n = 97) . | Arm B (n = 98) . |
|---|---|---|
| Sex, M/F, no. of patients | 49/48 | 50/48 |
| Age, y (range) | 53 (35–59) | 54 (34–59) |
| DS stage II/III, no. of patients | 15/82 | 14/84 |
| M component, no. of patients | ||
| IgG | 59 | 57 |
| IgA | 16 | 17 |
| Bence Jones | 22 | 24 |
| Hemoglobin, g/L (range) | 93 (53–121) | 94 (64–120) |
| Serum calcium, mmol/L (range) | 2.4 (2–4) | 2.5 (2.1–4) |
| Serum albumin, g/L (range) | 35 (20–42) | 34 (18–43) |
| Serum β-2 microglobulin, nmol/L (range) | 255 (85–1700) | 246.5 (93.5–1190) |
| Serum creatinine, μmol/L (range) | 100 (46–220) | 95 (43–226) |
| Bone marrow plasmocytosis, % of cells (range) | 35 (20–90) | 39 (25–80) |
| Chromosome 13, no. of patients (conventional cytogenetics) | ||
| No deletion | 56 | 58 |
| Deletion | 13 | 16 |
| Unknown | 28 | 24 |
| International Staging System, no. of patients | ||
| I | 27 | 29 |
| II | 31 | 30 |
| III | 39 | 39 |